購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huOPA1-del(c.2708-2711) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huOPA1-del(c.2708-2711) Mouse
製品名
huOPA1-del(c.2708-2711) Mouse
製品ID
C001933
系統名
C57BL/6JCya-Opa1tm1(hOPA1 c.2708_2711del TTAG)/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「huOPA1-del(c.2708-2711) Mouse(カタログ番号C001933)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Disease Animal Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Disease Animal Models
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
NPG, NTG, MGM1, BERHS, largeG, MTDPS14
NCBI ID
染色体
Chr 3
MGI ID
さらに
系統詳細
The OPA1 gene (Mitochondrial Dynamin Like GTPase) is a nuclear-encoded gene that is ubiquitously expressed in human tissues, with particularly high levels in the retina (specifically retinal ganglion cells), brain, heart, and skeletal muscle. It encodes a large dynamin-related GTPase protein that exists as eight distinct isoforms due to alternative splicing; these are further processed into membrane-anchored long forms (L-OPA1) and soluble short forms (S-OPA1) [1]. This protein localizes to the inner mitochondrial membrane and the intermembrane space, where it plays a critical functional role in mediating mitochondrial fusion, maintaining the structural integrity of cristae, and regulating cytochrome c sequestration to prevent apoptosis [2]. Mutations in OPA1 are primarily associated with Autosomal Dominant Optic Atrophy (ADOA), the most common form of hereditary optic neuropathy characterized by the progressive degeneration of retinal ganglion cells and blindness, as well as more severe "ADOA-plus" syndromes and Behr syndrome, which include multisystemic symptoms such as sensorineural deafness, ataxia, peripheral neuropathy, and chronic progressive external ophthalmoplegia (CPEO) [3-4]. The c.2708_2711del mutation is one of the most frequently reported causes of Autosomal Dominant Optic Atrophy (ADOA) worldwide.
The huOPA1-del(c.2708-2711) mouse is a humanized model with a c.2708_2711del TTAG mutation. In this model, the sequence from upstream of exon 1 to downstream of 3’UTR of the mouse Opa1 was replaced with the sequence from upstream of exon 1 to downstream of 3’UTR of the human OPA1. Specifically, the c.2708_2711del TTAG mutation is introduced into exon 27 of the human OPA1 gene. This model is suitable for the study of Autosomal Dominant Optic Atrophy (ADOA), as well as for the development of OPA1-targeted therapies.
参考文献
Lee H, Lee TJ, Galloway CA, Zhi W, Xiao W, de Mesy Bentley KL, Sharma A, Teng Y, Sesaki H, Yoon Y. The mitochondrial fusion protein OPA1 is dispensable in the liver and its absence induces mitohormesis to protect liver from drug-induced injury. Nat Commun. 2023 Oct 23;14(1):6721.
Zhang D, Zhang Y, Ma J, Zhu C, Niu T, Chen W, Pang X, Zhai Y, Sun F. Cryo-EM structures of S-OPA1 reveal its interactions with membrane and changes upon nucleotide binding. Elife. 2020 Mar 31;9:e50294.
Yao SQ, Liang JJ, Zhou H, Tan S, Cao Y, Chen CB, Xu C, Wang R, Li TP, Zhao FF, Wang Y, He HJ, Zhang D, Wang M, Liu L, Yu-Wai-Man P, Wei S, Cen LP. Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy. Cell Death Discov. 2025 May 30;11(1):259.
Jagadish S, Calhoun ARUL, Ganganna ST. Recurrent super-refractory status epilepticus and stroke like episode in a patient with Behr syndrome secondary to biallelic variants in OPA1 gene. Epilepsy Behav Rep. 2024 Feb 6;25:100652.
系統作製戦略
The sequence from upstream of exon 1 to downstream of 3’UTR of the mouse Opa1 was replaced with the sequence from upstream of exon 1 to downstream of 3’UTR of the human OPA1. The c.2708_2711del TTAG point mutation was introduced into exon 27 of the human OPA1 gene. The human EEF1A1P23 and OPA1-AS1 will be expressed in human genomic DNA.

Figure 1. Gene editing strategy of huOPA1-del(c.2708-2711) mice.
適用分野
Screening, development, and evaluation of OPA1-targeted drugs;
Research on the pathological mechanism and treatment methods of autosomal dominant optic atrophy (ADOA).
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
